What Clinicians Want You to Know About Tysabri and PML Risk

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Exposure Awareness

If you or someone you know is taking Tysabri, you may have heard concerns about a rare brain infection called progressive multifocal leukoencephalopathy (PML). Clinicians frame this risk within a broader context of treatment benefits and monitoring protocols. This page explains how medical experts evaluate the connection and what current reports say about safety. The concern is discussed within a growing body of medical literature and safety monitoring.

Understanding Tysabri and Its Link to Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC polyomavirus. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is a demyelinating disease that typically leads to death or severe disability. The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. Diagnosis relies on a combination of clinical evaluation, brain imaging (typically MRI showing demyelinating lesions), and laboratory detection of JC virus DNA in cerebrospinal fluid. In a large Italian retrospective cohort study of 456 PML patients observed between 1987 and 2024, 82.4% had a definite diagnosis and 17.6% had a clinico-radiological diagnosis (https://pubmed.ncbi.nlm.nih.gov/40922664/). This underscores the importance of prompt recognition in at-risk populations.

Mechanism of Action and Risk Factors for PML

The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces neuroinflammation but also impairs immune surveillance against JC virus, which is normally controlled by T cells. In the setting of reduced immune trafficking, latent JC virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. Risk factors for developing PML while on Tysabri include the presence of anti-JCV antibodies, longer duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefit when initiating or continuing treatment. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 multiple sclerosis patients treated for a median of 120 weeks; both had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) has identified thousands of adverse event reports associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, gait disturbance, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they highlight the range of neurological symptoms that may overlap with or obscure PML presentation.

Legal Considerations for Affected Individuals in Washington

The adequacy of warnings regarding Tysabri and PML is a critical risk anchor. The boxed warning explicitly states that Tysabri increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, with dosing withheld immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients and prescribers are informed of the risks. Despite these measures, questions may arise about whether warnings were sufficiently communicated to patients or whether early signs of PML were adequately recognized in individual cases. For affected patients and their families, attorney-related considerations may include evaluating whether the prescribing physician or manufacturer provided adequate risk information and whether timely monitoring and intervention occurred. The timeline between Tysabri exposure and documented harm is variable. In clinical trials, PML occurred after a median of 120 weeks of treatment in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, post-marketing experience suggests that PML can occur at any time during treatment, with risk increasing with longer duration. Patients who develop PML may face catastrophic outcomes, including permanent neurological disability or death, and may require lifelong care. In summary, Tysabri-associated PML is a serious adverse event with established risk factors and a defined mechanistic basis. The FDA has mandated strong warnings and a restricted distribution program, but individual cases may still raise questions about warning adequacy and clinical management. Patients and families affected by PML after Tysabri use may benefit from legal consultation to explore their options.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to Progressive Multifocal Leukoencephalopathy (PML)?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of PML, a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms and diagnosis of PML in Tysabri patients?

Symptoms include progressive weakness, gait disturbance, cognitive impairment, and visual changes. Diagnosis involves MRI showing demyelinating lesions and detection of JC virus DNA in cerebrospinal fluid. A large study found 82.4% of PML cases had a definite diagnosis (https://pubmed.ncbi.nlm.nih.gov/40922664/).

What legal options are available for individuals who developed PML after Tysabri use in Washington?

Affected individuals may consult an attorney to evaluate whether adequate warnings were provided and whether monitoring was appropriate. Legal action may be possible against the manufacturer or healthcare providers for failure to warn or timely diagnose PML.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.